Navigation Links
XYOTAX in Medical News

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results

...operating expenses in 2008, by focusing resources on reaching $15 million in net Zevalin revenues, pursuing European marketing authorization (MAA) for xyotax (paclitaxel poliglumex, CT-2103), preparing for a potential U.S. marketing application (NDA) for pixantrone (BBR 2778) in 2009, and supporting the adv...

Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009

...tates and preparing the marketing applications for xyotax (paclitaxel poliglumex, CT-2103) and pixantrone (B... some phase III clinical trials for pixantrone and xyotax until planned regulatory filings and the completio...uct approvals. CTI expects to file for approval of xyotax in Europe in March. The Company will expand its co...

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

... O'Byrne, M.D., presented the phase III results of xyotax in first-line treatment of non-small cell lung can...." Dr. O'Byrne also presented data suggesting that xyotax may be particularly effective in women with pre-me...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results

...ion of ZEVALIN, coupled with progress on advancing xyotax toward a first half 2008 marketing application sub... phase III clinical trials, PGT307 and PIX303, for xyotax and pixantrone (BBR 2778), respectively. Including...pared to currently marketed anthracyclines. About xyotax XYOTAX(TM) (paclitaxel poliglumex) is a biologica...

Multiple deaths forces cancer trial to be called off

...d in a big way with enrollment made at 170 medical centers globally last April, and had planned to study about 600 patients to prove the efficacy of xyotax in increasing the life span of patients with lung cancer using a regularly used chemotherapy agent coupled with a polymer which is supposed to help in...

Experimental Drug Reduces Tumor Size When Given With Radiation

... An experimental drug xyotax was successful in shrinking stomach and esophagus tumors in four out of 12 cancer patients, according to its maker Cell Therapeutics.// The other pati...
XYOTAX in Medical Technology

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

... beginning of March. The validation of the MAA for xyotax initiates the marketing approval review process, w...of the MAA. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

... xyotax to be reviewed for PS2 first-line non-small cell l...LAR trials. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

...source utilization (MRU) and associated costs with xyotax (paclitaxel polyglumex) treatment compared to gemc... average treatment cost, excluding drug costs, for xyotax patients was nearly half the cost of treatment for...tional, randomized trial (STELLAR 4) that compared xyotax (n=191) to gemcitabine or vinorelbine (n=190) in p...
XYOTAX in Biological Technology

Veteran Drug Industry Executive to Become President of CTI

...ation for FDA approval in late 2008 or early 2009. xyotax is also being studied independently in a phase III... negotiate an exclusive license for pixantrone. If xyotax receives regulatory approval in the U.S. or Europe...ir intended uses, a determination by the EMEA that xyotax should not be approved for sale in Europe, other d...

Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008

...resources to the GOG212 trial, a clinical trial of xyotax in first-line maintenance ovarian cancer being per... in the second half of 2009. The clinical trial of xyotax in combination with carboplatin in women with pre-...for the Company is to focus resources on obtaining xyotax and pixantrone approval with existing or completin...

Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

...he STELLAR 4 phase III clinical trial results, for xyotax as a single agent for first-line treatment of non-...al The STELLAR 4 phase III clinical trial tested xyotax versus either gemcitabine or vinorelbine for the p...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

... significantly shorter than post-menopausal women. xyotax (TM) (paclitaxel poliglumex) will be studied in co...tion (MAA) in Europe in the first half of 2008 for xyotax as a single agent for first-line treatment of NSCL... 225 patients will be randomized to receive either xyotax 175mg/m2 plus carboplatin (AUC6) or paclitaxel 225...
Other Tags
(Date:7/28/2015)... ... July 28, 2015 , ... A ... shipbreaking workers than they are in the general population. Surviving Mesothelioma has just ... now. , Researchers at Taiwan’s National Health Research Institutes and three Taiwanese ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Fertility ... chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top ... by hundreds of her esteemed colleagues and peers in the metro area as one ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... Breakdown of Mets' David Wright's Spinal Stenosis Injury" discussed baseball player David Wright’s ... stenosis is acquired lumbar stenosis, brought on by degenerative changes in the spine, ...
(Date:7/28/2015)... Mountain View, CA (PRWEB) , ... July 28, ... ... Organic Coconut Water line has won the 2015 NCW Eco-Excellence Award for the ... adult, child and pet lifestyle industries and elevate companies that stand out for ...
(Date:7/28/2015)... Myers, Florida (PRWEB) , ... July 28, 2015 ... ... Ltd., America's trusted source for identifying Top Doctors, has based its selection process ... are the most outstanding in their medical specialties, in any area of medicine ...
Breaking Medicine News(10 mins):Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
Other Contents